达格列净在慢性肾脏病患者中跨主要地理区域的疗效与安全性
本研究基于DAPA-CKD试验(NCT03036150),按地理区域分析达格列净在慢性肾脏病(CKD)患者中的疗效与安全性。纳入4304例患者,随机接受达格列净10 mg每日一次或安慰剂。结果显示达格列净在各区域均降低主要复合终点相对风险,无区域效应修饰(交互P=0.77),严重不良事件发生率在达格列净组低于安慰剂组。
要点
- 达格列净降低主要复合终点风险,亚洲、欧洲、拉丁美洲、北美HR分别为0.70、0.60、0.61、0.51,交互P=0.77。
- 严重不良事件发生率在达格列净组低于安慰剂组,各区域分别为21.9% vs 26.8%、34.1% vs 38.6%、29.8% vs 31.5%、34.9% vs 41.0%。
- 达格列净减少肾脏和心血管事件并延长生存,有无2型糖尿病均一致,无区域效应修饰。
核心结论
- 达格列净降低CKD患者(伴或不伴2型糖尿病)的肾脏和心血管事件并延长生存,无地理区域效应修饰。
研究设计与样本
- DAPA-CKD试验(NCT03036150)事后按地理区域分析,纳入eGFR 25-75 ml/min/1.73 m2且UACR 200-5000 mg/g的成人CKD患者,随机接受达格列净10 mg每日一次或安慰剂。
- 共纳入4304例随机患者,其中亚洲1346例(31.3%)、欧洲1233例(28.6%)、拉丁美洲912例(21.2%)、北美813例(18.9%)。
主要发现
- 主要复合终点(eGFR持续下降≥50%、终末期肾病或肾脏/心血管原因死亡)的相对风险在达格列净组各区域均低于安慰剂组,HR(95%CI)亚洲0.70(0.48-1.00)、欧洲0.60(0.43-0.85)、拉丁美洲0.61(0.43-0.86)、北美0.51(0.34-0.76)。
- 区域交互作用P=0.77,无效应修饰。
- 严重不良事件发生率在达格列净组低于安慰剂组,亚洲21.9% vs 26.8%、欧洲34.1% vs 38.6%、拉丁美洲29.8% vs 31.5%、北美34.9% vs 41.0%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to examine the efficacy and safety of dapagliflozin in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (NCT03036150) by geographic region. METHODS: Adults with chronic kidney disease (CKD) with or without type 2 diabetes, with estimated glomerular filtration rate (eGFR) 25 to 75 ml/min per 1.73 m2 and urinary albumin-to-creatinine ratio (UACR) 200 to 5000 mg/g were randomized to dapagliflozin (10 mg once daily) or placebo. The primary end point was a composite of a sustained decline in eGFR of ≥50%, end-stage kidney disease or death from kidney or cardiovascular causes. We categorized recruiting countries into 4 broad global regions: Asia, Europe, Latin America, and North America. Of 4304 randomized patients, 1346 (31.3%) were from Asia, 1233 (28.6%) from Europe, 912 (21.2%) from Latin America, and 813 (18.9%) from North America. RESULTS: The relative risk of the primary composite end point was lower in patients randomized to dapagliflozin (relative to placebo) in all regions, with hazard ratios (95% CI) of 0.70 (0.48-1.00), 0.60 (0.43-0.85), 0.61 (0.43-0.86), and 0.51 (0.34-0.76) among patients from Asia, Europe, Latin America, and North America, respectively. There was no effect modification by region (interaction P = 0.77). Occurrence of serious adverse events (SAEs) was lower among patients randomized to dapagliflozin versus placebo (21.9% vs. 26.8%, 34.1% vs. 38.6%, 29.8% vs. 31.5%, and 34.9% vs. 41.0% in Asia, Europe, Latin America, and North America, respectively). CONCLUSION: Dapagliflozin reduced kidney and cardiovascular events and prolonged survival in patients with CKD, with and without type 2 diabetes, with no apparent effect modification by geographic region.
引用
- Vart P, Correa-Rotter R, Hou FF, et al. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. Kidney Int Rep. 2022. PMID: 35497805. doi:10.1016/j.ekir.2022.01.1060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。